MedTrace Logo

Single-dose Vaginal Dinoprostone and Hysterectomy

NCT04080323 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2020-08-27

No results posted yet for this study

Summary

In this study, we will assess the efficacy of dinoprostone in minimizing blood loss during hysterectomy when used as a single preoperative dose via the vaginal route. The reduction of blood flow may be due to the combined effect of myometrial contraction and vasoconstrictive effect

Conditions

  • Hysterectomy

Interventions

DRUG

Dinoprostone 3 mg

1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery

DRUG

placebo

1 vaginal tablet of placebo 60 minutes before surgery

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • AHMED SAMY · Cairo University

  • ayman taher, MD · Cairo University

  • ahmed S Ali · faculty of medicine al-azhar university

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-25
Primary Completion
2020-05-30
Completion
2020-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04080323 on ClinicalTrials.gov